These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 11921428)

  • 21. Technosphere insulin technology.
    Richardson PC; Boss AH
    Diabetes Technol Ther; 2007 Jun; 9 Suppl 1():S65-72. PubMed ID: 17563306
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
    Plosker GL; Figgitt DP
    Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Inhaled human insulin.
    Strack TR
    Drugs Today (Barc); 2006 Apr; 42(4):207-21. PubMed ID: 16703118
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dose-response relationship of an oral insulin spray in six patients with type 1 diabetes: a single-center, randomized, single-blind, 5-way crossover study.
    Cernea S; Kidron M; Wohlgelernter J; Raz I
    Clin Ther; 2005 Oct; 27(10):1562-70. PubMed ID: 16330292
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Safety, efficacy and glucose turnover of reduced prandial boluses during closed-loop therapy in adolescents with type 1 diabetes: a randomized clinical trial.
    Elleri D; Biagioni M; Allen JM; Kumareswaran K; Leelarathna L; Caldwell K; Nodale M; Wilinska ME; Haidar A; Calhoun P; Kollman C; Jackson NC; Umpleby AM; Acerini CL; Dunger DB; Hovorka R
    Diabetes Obes Metab; 2015 Dec; 17(12):1173-9. PubMed ID: 26257323
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Insulin lispro: its role in the treatment of diabetes mellitus.
    Campbell RK; Campbell LK; White JR
    Ann Pharmacother; 1996 Nov; 30(11):1263-71. PubMed ID: 8913409
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Direct comparison among oral hypoglycemic agents and their association with insulin resistance evaluated by euglycemic hyperinsulinemic clamp: the 60's study.
    Derosa G; Maffioli P; Salvadeo SA; Ferrari I; Gravina A; Mereu R; Palumbo I; D'Angelo A; Cicero AF
    Metabolism; 2009 Aug; 58(8):1059-66. PubMed ID: 19394976
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treating diabetes with aerosolized insulin.
    Laube BL
    Chest; 2001 Sep; 120(3 Suppl):99S-106S. PubMed ID: 11555563
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Unlocking the opportunity of tight glycaemic control. Innovative delivery of insulin via the lung.
    Patton JS
    Diabetes Obes Metab; 2005 Nov; 7 Suppl 1():S5-8. PubMed ID: 16135136
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The Effect of DPT-1 Intravenous Insulin Infusion and Daily Subcutaneous Insulin on Endogenous Insulin Secretion and Postprandial Glucose Tolerance.
    Hao W; Greenbaum CJ; Krischer JP; Cuthbertson D; Marks JB; Palmer JP
    Diabetes Care; 2015 May; 38(5):891-6. PubMed ID: 25720600
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Artificial Pancreas Project at Cambridge 2013.
    Hovorka R
    Diabet Med; 2015 Aug; 32(8):987-92. PubMed ID: 25819473
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Effect of acarbose on postprandial increase in blood glucose. Additive acute effect of once daily administration in insulin treated diabetes].
    Ledermann H; Höxter G
    Fortschr Med; 1994 Nov; 112(32):467-70. PubMed ID: 7821886
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Delivery of insulin to the buccal mucosa utilizing the RapidMist system.
    Bernstein G
    Expert Opin Drug Deliv; 2008 Sep; 5(9):1047-55. PubMed ID: 18754753
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Inhaled insulin as adjunctive therapy in subjects with type 2 diabetes failing oral agents: a controlled proof-of-concept study.
    Hausmann M; Dellweg S; Osborn C; Heinemann L; Buchwald A; Rosskamp R; Genova P; Heise T
    Diabetes Obes Metab; 2006 Sep; 8(5):574-80. PubMed ID: 16918593
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Review of phase 2 studies utilizing the AIR particle technology in the delivery of human insulin inhalation powder versus subcutaneous regular or lispro insulin in subjects with type 1 or type 2 diabetes.
    Ellis SL; Gemperline KA; Garg SK
    Diabetes Technol Ther; 2007 Jun; 9 Suppl 1():S48-56. PubMed ID: 17563304
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Used of oral antidiabetic agents in pediatric patients - own observations].
    Stańczyk J; Otto-Buczkowska E; Jarosz-Chobot P; Nowowiejska B
    Endokrynol Pol; 2008; 59(5):434-43. PubMed ID: 18979454
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacokinetics and pharmacodynamics of metformin in healthy subjects and patients with noninsulin-dependent diabetes mellitus.
    Sambol NC; Chiang J; O'Conner M; Liu CY; Lin ET; Goodman AM; Benet LZ; Karam JH
    J Clin Pharmacol; 1996 Nov; 36(11):1012-21. PubMed ID: 8973990
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Rethinking the Viability and Utility of Inhaled Insulin in Clinical Practice.
    Heinemann L; Parkin CG
    J Diabetes Res; 2018; 2018():4568903. PubMed ID: 29707584
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The role of prandial pramlintide in the treatment of adolescents with type 1 diabetes.
    Rodriguez LM; Mason KJ; Haymond MW; Heptulla RA
    Pediatr Res; 2007 Dec; 62(6):746-9. PubMed ID: 17957149
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The number of basal rates required to achieve near-normal basal glucose control in pump-treated type 2 diabetes.
    King AB; Clark D; Wolfe GS
    Diabetes Technol Ther; 2012 Oct; 14(10):900-3. PubMed ID: 22845649
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.